

MATERIAL SAFETY DATA SHEET

Version 001 - 04. April 2016

Supersedes: new

1. COMPOUND IDENTITY/FORMULATION AND COMPANY INFORMATION

Description of compound or formulation

CDA-25-S.10 Article number:

Litak® 10 (solution for subcutaneous injection or intrave-Common/Trade Name:

nous infusion: vials containing 10 mg/5 m

2-chloro-2'-deoxyadenosine **Chemical Names:**

Synonyms

Cladribinum, 2-Chloro-2'-deoxy-b-D-adenosinum, 2-CdA, 2-chlorodeoxyadenosine, Cladribine

Manufacturer's/Supplier's information

Manufacturer's Name: Lipomed AG

Fabrikmattenweg Address:

CH-4144 Arlespeim Tel: 0041 6 02 02 00 E-Mail: save@lipomed.com

0041 81 702 02 20 **Emergency Telefax Number:**

Address for detailed scientific information

LIPOMED AG

Fabrikmattenweg 4 CH-4144 Arlesheim

Switzerland

Tel.: 0041 61 702 02 00 Fax: 0041 61 702 02 20 E-Mail: save@lipomed.com

2. HAZARDOUS INGREDIENTS/COMPOSITION INFORMATION

CAS# Component <u>%</u>

2-CdA 0.2 4291-63-8

3. HEALTH HAZARD DATA

Routes of Entry: Product may be absorbed via ingestion or skin contact.

Date: 04.04.2016

Issued: S. Lombardi Borgia

Date: 0404.2016 Checked: P. Wolff

Date: 04.94 2016 QA-approved: D. Foechterlen



Health Hazard (Acute & Chronic): It is a possible human teratogen. LITAK® may

affect the digestive and central nervous systems. Product affects the blood forming systems, liver, and kidneys. LITAK® is fetotoxic.

Carcinogenicity: NTP? NO IARC Monographs? NONE OSHA Regulated? NO

Signs & Symptoms of Exposure:

May cause irritation to eyes, skin and respiratory system or skin rash. May cause fatigue, headache, nausea, vomiting and dizziness and a variety of other systemic effects.

4. FIRST AID MEASURES

Inhalation: Not applicable (water solution)

Skin Exposure: Wash skin with copious amounts of soapy water.

Eye Exposure: Flush eyes with large amounts of water for 15 minutes.

Seek attention of a physician.

Ingestion: If ingestion occurs, flush mouth with water and seek medical attention

immediately. If person is conscious and medical assistance is not available,

induce vomiting.

5. FIRE AND EXPLOSION HAZARD DATA

Flash point (Method Used): Not applicable (water solution)

Flammable Limits: Not applicable LEL: Not applicable UEL: Not applicable

Unusual Fire/Explosion Hazards: None

6. ACCIDENTAL RELEASE INFORMATION

Release to Kand: Absorb LITAK® with towels or absorbents and dispose of with 0.1 N HCl

solution according to local, state and federal regulations.

Wear appropriate protective equipment. Prevent spills from entering

drains or sewers. Wash area with 0.1 N HCl solution.

Release to Water: Refer to local water authority. Drain disposal is not recommended.

7. PRECAUTIONS FOR SAFE HANDLING AND USE

Instructions for proper handling and disposal of antineoplastic drugs should be considered according to the guidelines for the handling with and disposal of cytotoxic drugs. Cautions handling with LITAK® and with the prepared infusion is required.

The use of disposable gloves, protective glasses and garments are recommended to avoid the direct contact with the drug.

Date: 04.04.2016 Issued: S. Lombardi Borgia Date: 04.04.16 Checked: P. Wolff Date: Ou Signature 2016

QA-approved: D. Foechterlen

2/4



8. CONTROL MEASURES AND PERSONAL PROTECTIVE EQUIPMENT

Protective Gloves: Latex or nitrile

Eye Protection: Safety glasses

Other Protective Clothing or Equipment:

Necessary clothing to prevent skin contact such as a lab coat with a closed front, long sleeves, or elastic cuffs.

Work/Hygienic Practices:

Wash hands following use. No eating, drinking or smoking while handling this product

9. PHYSICAL/CHEMICAL CHARACTERISTICS

Physical state: Aqueous solution (2 mg/m/in 0.9% NaCl solution)

Appearance and Odour: Clear, colourless solution with no odour

pH: 6.5-7.5

Melting Point: Not applicable

Boiling point: 100 °C

Vapour Pressure:

Relative Density:

Not applicable 1,0059

Relative Density: (Specific Gravity)

Vapour Density:

Evaporation Rate:

Not applicable

Not applicable

Solubility in Water: Somble

10. STABILITY AND REACTIVITY DATA

Stability

Stable. Product is decomposed to 2-Chloro-6-aminopurine and 2-Deoxy-D-ribose by acidic pH 1. Avoid strong oxidizers or water reactive materials.

11. TOXICOLOGICAL INFORMATION

Acute toxicity (single dose toxicity)

Mouse, intraperitoneal MTD = $120 \text{ mg/kg} (360 \text{ mg/m}^2)$

 $LD_{50} = 150 \text{ mg/kg } (450 \text{ mg/m}^2)$ $LD_{90} = 180 \text{ mg/kg } (540 \text{ mg/m}^2)$

Chronic toxicity (repeated dose toxicity)

Mouse, intraperitoneal MTD = 50 mg/kg/day

 $LD_{50} = 75 \text{ mg/kg/day}$ $LD_{90} = 100 \text{ mg/kg/day}$

Human, man $TD_{LO} = 700 \mu g/kg//7D-C$

Date: 04.04.2016

Issued: S. Lombardi Borgia

Date: O4.04-16 Checked: P. Wolff

Checked: P. Wolff

Date: O4 2016 QA-approved: D. Foechterlen

3/4



12. ENVIRONMENTAL IMPACT INFORMATION

N-Octanol/water parturition coefficient:

0.551

LITAK® does not present a risk for the environment.

Therefore no others detailed environmental effect analysis and further testing are available.

13. DISPOSAL INFORMATION

Dispose of via incineration at an approved/permitted waste disposal facility according to fed-LICITACION eral, state and local guidelines or decompose with 0.1 N HCl solution.

14. TRANSPORTATION INFORMATION

LITAK® is not a hazardous material.

Storage:

cooled +2°C up to +8°C

Dispatch:

feasible at room temperature

interim storage for max. 2 weeks

15. REGULATORY INFORMATION

R-Phrases

R-45 May cause cancer.

May cause heritable genetic damage. R-46

May impair fertility R-60

May cause harm to the unborn child. R-61

S-Phrases

In case accident or if you feel unwell, seek medical advice immediately S-45

(show the label where possible).

void exposure - obtain special instructions before use. S-53

16. OTHER DATA

Aseptic conditions must be observed while handling with LITAK® and preparing the infusions. LITAK® should be administered under the supervision of a qualified physician with experience in cancer chemotherapy.

This information is given without any warranty or representation.

It is believed to be correct but does not claim to be all inclusive and shall be used only as a quide. Lipomed AG shall not be held liable for any damage resulting from handling or contact with the above products. It is offered solely for your consideration, investigation and verification.

Date: 04.04.2016

Issued: S. Lombardi Borgia

Date: 04-04-16 Checked: P. Wolff Date: 04 54 2016 QA-approved: D. Foechterlen